1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Castle Medical Labs

Anonymous board for Castle Medical Labs

Sort By:
Title
Replies Views
Last Message ↓
  1. anonymous
    Replies:
    7
    Views:
    4,557
  2. anonymous
    Replies:
    11
    Views:
    2,498
  3. anonymous
    Replies:
    45
    Views:
    13,001
  4. anonymous
    Replies:
    4
    Views:
    1,359
  5. anonymous
    Replies:
    28
    Views:
    5,858
  6. anonymous
    Replies:
    14
    Views:
    2,813
  7. anonymous
    Replies:
    13
    Views:
    3,141
  8. anonymous
    Replies:
    4
    Views:
    1,545
  9. anonymous
    Replies:
    25
    Views:
    4,847
  10. anonymous
    Replies:
    0
    Views:
    1,440
  11. Anonymous
    Replies:
    12
    Views:
    3,540
  12. anonymous
    Replies:
    10
    Views:
    2,323
  13. Anonymous
    Replies:
    12
    Views:
    2,870
  14. Anonymous
    Replies:
    121
    Views:
    45,283
  15. Anonymous
    Replies:
    11
    Views:
    2,652
  16. Anonymous
    Replies:
    6
    Views:
    2,849
  17. anonymous
    Replies:
    3
    Views:
    2,169
  18. anonymous
    Replies:
    7
    Views:
    3,018
  19. anonymous
    Replies:
    6
    Views:
    4,095
  20. anonymous
    Replies:
    4
    Views:
    2,492

Thread Display Options

Loading...